三諾生物(300298.SZ)上半年淨利同比降22.94%經營性現金流大幅轉正
格隆匯8月15日丨三諾生物(300298.SZ)披露2019年半年度報告,報告期內公司實現營業總收入8.15億元,同比增長6.98%;歸屬於上市公司股東的淨利潤1.30億元,同比下降22.94%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.22億元,同比下降10.37%;經營活動現金淨流入2.08億元,而上年同期淨流出606.82萬元;基本每股收益0.2292元。
報告期內,公司圍繞發展戰略和2019年經營計劃有序開展各項工作,加速佈局以患者為中心的全病程管理,重點加大核心產品和新產品的市場推廣,加大對醫院市場、基層醫療市場、國際市場以及非血糖檢測產品的開拓力度,不斷提升客户服務和直連用户的能力,進一步豐富公司慢病管理相關的監測產品線。
同時,由於一方面公司去年同期完成收購三諾健康管理有限公司64.98%股份,在合併日對原持有股權確認了股權增值部分的投資收益約2,300萬元,另一方面,受市場環境及國際銷售等因素影響,公司參股子公司深圳市心諾健康產業投資有限公司2019年上半年度處於經營虧損狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.